

February 27, 2020

Medos International SARL Michael Liao Senior Regulatory Affairs Program Lead Chemin-Blanc 38 Le Locle, 2400, Switzerland

Re: K192804

Trade/Device Name: CEREBASE DA Guide Sheath

Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter

Regulatory Class: Class II

Product Code: QJP Dated: January 29, 2020 Received: January 30, 2020

Dear Michael Liao:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

K192804 - Michael Liao Page 2

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Xiaolin Zheng, Ph.D., M.S.
Director
DHT5A: Division of Neurosurgical,
Neurointerventional
and Neurodiagnostic Devices
OHT5: Office of Neurological
and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known)

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2020 See PRA Statement below.

| K192804 | | | |
|--|--|--|--|
| Device Name | | | |
| CEREBASE DA Guide Sheath | | | |
| | | | |
| Indications for Use (Describe) | | | |
| The CEREBASE DA Guide Sheath is indicated for the introdu- | ction of interventional devices into the neuro | | |
| vasculature. | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Type of Use (Select one or both, as applicable) | | | |
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) | | |
| | | | |
| CONTINUE ON A SEPARA | ATE PAGE IF NEEDED. | | |

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff @fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

I. Submitter Medos International, SARL

Chemin-Blanc 38

2400 Le Locle, Switzerland

Tel: (510) 770-5376

Contact Person: Michael Liao

Email of Contact Person: mliao7@its.jnj.com

Date Prepared: January 28, 2020

II. Device

| Table 1. Device | | | |
|--|--|--|--|
| Device Proprietary Name CEREBASE DA Guide Sheath | | | |
| Common or Usual Name | Catheter, Percutaneous, Neurovasculature | | |
| Classification Name Catheter, Percutaneous, Class II, 21 C.F.R. 870.1250 | | | |
| Regulatory Classification | II | | |
| Product Code | QJP | | |

III. Predicate Device

The predicate device is listed below in Table 2.

| Table 2. Prior 510(k) Clearance | | | |
|---------------------------------|--------------|---------------------------|--------------------------|
| 510(k) Number | Date Cleared | Name | Manufacturer |
| K111380 | 07/19/2011 | Neuron MAX System | Penumbra, Inc. |
| K140080 | 04/24/2014 | ENVOY DA Guiding Catheter | Medos International SARL |
| K140307 | 04/21/2014 | ENVOY Guiding Catheter | Codman & Shurtleff, Inc. |

IV. Device Description

The CEREBASE DA Guide Sheath is a single lumen, stainless steel braided catheter of variable stiffness with a large non-tapered lumen that facilitates the intravascular passage of interventional devices. The guide sheath is a straight shaped catheter that comes in four lengths; 70 cm, 80 cm, 90 cm, and 95 cm. The lubricious PTFE-lined inner lumen is designed to facilitate delivery of the interventional devices. It has a radiopaque marker band on the distal end and a luer hub at the proximal end. The guide sheath has an outer hydrophilic coating at the distal end that reduces friction during use. A hemostasis valve and a dilator are provided with the CEREBASE DA Guide Sheath within its sterile packaging. The dilator is a single lumen radiopaque catheter with a tapered distal end and a luer hub at the proximal end. The dilator is compatible with the CEREBASE DA Guide Sheath and up to 0.038 inch diagnostic guidewires. The hemostasis valve with side port is an off the shelf component used for flushing and insertion of catheters.

IV. Device Description, Continued

The CEREBASE DA Guide Sheath's lumen must be flushed and outer body wet with heparinized saline solution prior to use. If using as a primary access sheath with the dilator, the dilator must be soaked and flushed with heparinized saline solution as well prior to use. After being flushed with heparinized saline solution the dilator can then be inserted and advanced until the tapered distal tip is beyond the distal end of the CEREBASE DA Guide Sheath. Then the hemostasis valve is closed around the dilator and primary access can be gained to the vasculature using a standard technique of choice.

V. Indications for Use

The CEREBASE DA Guide Sheath is indicated for the introduction of interventional devices into the neuro vasculature.

VI. Comparison of Technological Characteristics with Predicate Device

Table 3 below provides comparison of technological characteristics with the predicate device. Based on design verification and validation testing, the minor differences in characteristics do not raise different questions of safety and effectiveness.

| | Table 3. Technological Characteristic Comparison | | | |
|----------------------------------|--|---|--|--|
| Description | CEREBASE DA Guide Sheath – Subject Device | Neuron MAX (K111380) | | |
| Indications | The CEREBASE DA Guide Sheath is indicated for the introduction of interventional devices into the neuro vasculature. | The Neuron MAXX System is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature | | |
| Lengths | 70 cm 80 cm 90 cm 95cm | 80 cm 90 cm | | |
| Shapes | Straight | Straight, MP | | |
| Outside Diameter | 8F | 8F | | |
| Inside Diameter | 0.090" | 0.088" | | |
| Tip Length | 1 mm | 2mm | | |
| Hub Material | Polycarbonate (yellow) | | | |
| Shaft Material | Nylon Segment(s) Pebax (nylon blend) Segment(s) Polyurethane Segment(s) | Nylon, Polyurethane | | |
| Inner Lining | PTFE | PTFE | | |
| Outer Coating | Hydrophilic Coating | Hydrophilic Coating | | |
| Shaft Braid | 304 Stainless Steel | Stainless Steel | | |
| Outer Jacket Material Segment | 11 outer jacket material segments of different | 5 outer jacket material segments of different durometer | | |
| Distal Tip Radiopaque Marker | Metal Marker Band | Radiopaque Filler and Metal Marker band | | |
| Hemostasis Valve | Yes | Yes | | |
| Dilator | Yes | Yes | | |
| Dilator Material | Polyethylene | Polyethylene | | |
| Packaging | PET/ LDPE Tyvek Pouch Polypropylene Tubing SBS Mounting Card SBS Carton | PET/PE/ Tyvek Pouch HPDE Tubing Mounting Card Carton | | |
| Sterilization Method | EtO | EtO | | |
| Shelf Life | 1 year | 3 years | | |

VII. Non-Clinical Data Performance The design verification and validation testing activities were conducted on the CEREBASE DA Guide Sheath to ensure that design outputs met design inputs. **Table 4** below provides a description and result of each of these performance tests.

| Table 4. Performance Testing | | | |
|------------------------------------|---|---|--|
| Test | Test Method Summary | Results | |
| Visual Inspection | The purpose of this test was to verify that the test samples meet the visual requirements of ISO 10555-1. | Pass. Samples passed established acceptance criteria. | |
| Catheter Internal Diameter (ID) | The purpose of this test was to verify that the catheter internal diameter meets requirements. The inner diameter of each sample was measured. | Pass. Samples passed established acceptance criteria. | |
| Catheter Outer Diameter (OD) | The purpose of this test was to verify that the catheter outer diameter meets requirements. The outer diameter of each sample was measured. | Pass. Samples passed established acceptance criteria. | |
| Catheter Working Length | The purpose of this test was to ensure the working length meets requirements. The length of the catheter was measured. | Pass. Samples passed established acceptance criteria. | |
| Distal Tip Length | The purpose of this test was to ensure the distance of the distal edge of the marker band to the tip of the catheter meets requirements. | Pass. Samples passed established acceptance criteria. | |
| Hub Luer Taper | The purpose of this test was to verify that the catheter hub luer taper fits standard luer fittings using a taper device. | Pass. Samples passed established acceptance criteria. | |
| Air Leak Test | The purpose of this test was to verify that there are no air leaks into the hub subassembly. The samples were inspected to ensure no air bubbles that may indicate a hub air leak. | Pass. Samples passed established acceptance criteria. | |
| Liquid Leak Test | The purpose of this test was to ensure that the catheter joint strength meets the freedom from leakage requirements (liquid during pressurization) requirements of ISO 10555-1. | Pass. Samples passed established acceptance criteria. | |
| Static Burst | The purpose of this test was to verify the maximum hydrostatic pressure meets requirements of ISO 10555-1. | Pass. Samples passed established acceptance criteria. | |
| Hub Pull Testing | The purpose of this test was to verify that the strength of the catheter hub meets the requirements of ISO 10555-1. A tensile tester measured the tensile strength of the joint. | Pass. Samples passed established acceptance criteria. | |
| Shaft Tensile Strength | The purpose of this test was to verify that the strength of the catheter shaft meets the requirements of ISO 10555-1. A tensile tester measured the tensile strength of the distal section of the catheter shaft. | Pass. Samples passed established acceptance criteria. | |
| Particulate Count | The purpose of this test was to quantify the particulate count generated by simulated use of the test samples. | Pass. Samples passed established acceptance criteria. | |
| Coating Lubricity | The purpose of this test was to measure the lubricity of the coating. The test samples were put through a lubricity tester to measure frictional force. | Pass. Samples passed established acceptance criteria. | |
| Coating Durability | The purpose of this test was to measure the durability of the lubricious coating layer. | Pass. Samples passed established acceptance criteria. | |
| Coating Length | The purpose of this test was to verify that the catheter hydrophilic coating length meets the design requirement. | Pass. Samples passed established acceptance criteria. | |
| Kink Resistance | The purpose of this test was to confirm the catheter met requirement for stability and did not kink during use. | Pass. Samples passed established acceptance criteria. | |
| Delamination of PTFE Liner | The purpose of this test was to verify that the PTFE is appropriately adhered to the inner lumen of the catheter with braid reinforcement. | Pass. Samples passed established acceptance criteria. | |

VII. Non-Clinical Data Performance, Continued

| Table 4. Performance Testing, Continued | | | |
|---|--|---|--|
| Test | Test Method Summary | Results | |
| Backup Support | The purpose of this test was to measure the stability of the test sample while advancing other interventional devices through its lumen. A wire was pushed through the lumen of each test sample and the force at which catheter support failed was measured. | Pass. Samples passed established acceptance criteria. | |
| Tip Linear Stiffness | The purpose of this test was to evaluate the flexibility of the catheter relative to other devices of similar design. | Pass. Samples passed established acceptance criteria. | |
| Dilator Visual Inspection | The purpose of this test was to verify that the dilator was free of extraneous matter per ISO 11070. | Pass. Samples passed established acceptance criteria. | |
| Dilator Inner Diameter (ID) | The purpose of this test was to verify that the dilator internal diameter meets requirements. | Pass. Samples passed established acceptance criteria. | |
| Dilator Hub Luer Taper | The purpose of this test was to verify that the dilator fits standard luer fittings using a tapered device. | Pass. Samples passed established acceptance criteria. | |
| Insertion Forces | The purpose of this test was to measure the forces required to insert the dilator and catheter into a simulated model. | Pass. Samples passed established acceptance criteria. | |
| Dilator Outer Diameter (OD) | The purpose of this test was to verify that the dilator outer diameter meets requirements. | Pass. Samples passed established acceptance criteria. | |
| Dilator Working Length (WL) | The purpose of this test is to verify the working length of the dilator to ensure compatibility with the catheter. | Pass. Samples passed established acceptance criteria. | |
| Dilator Tensile Strength | The purpose of this test was to verify that the dilator joint strength meets the requirements of ISO 11070. | Pass. Samples passed established acceptance criteria. | |
| Torque (Turns to Failure) | The purpose of this test is to count the number of turns the catheter can withstand without separating. | Pass. Samples passed established acceptance criteria. | |
| Trackability | The purpose of this test is the measure of the force required to advance the catheter through a simulated vascular model. | Pass. Samples passed established acceptance criteria. | |
| In Vitro Modeling and In Vivo Testing | The purpose of In Vitro modeling and In Vivo testing in a porcine model were to ensure that design outputs meet the customer requirements. | Pass. Samples passed established acceptance criteria. | |

VII. Non-Clinical Data Performance, Continued

Shelf Life

One year accelerated aging was successfully performed on the CEREBASE DA Guide Sheath. Additionally, through review of package integrity testing and previous testing with a sterile pouch made of the same material combination, the sterile pouch is confirmed to have a shelf life of at least one year. The shelf life of the CEREBASE DA Guide Sheath is established as one year.

Packaging Qualification

The CEREBASE DA Guide Sheath was sterilized, packaged and subjected to conditioning and simulation testing for worst case conditions per ISTA 3A: 2018, Packaged-Products for parcel Delivery System Shipment 70Kg (150 lb) or less. The samples were used to validate the package integrity of the CEREBASE DA Guide Sheath per EN ISO 11607-1:2009, Packaging for terminally sterilized medical devices – Part 1: Requirements for materials, sterile barrier systems and packaging systems.

VII. Non-Clinical Data Performance, Continued The following packaging qualification testing was completed as part of this evaluation:

| Table 5. Packaging Qualification | | | |
|----------------------------------|--------|--|--|
| Test | Result | | |
| Visual Inspection | PASS | | |
| Dye Leak Penetration | PASS | | |
| Seal Strength | PASS | | |
| Shelf Life | PASS | | |
| Biocompatibility | PASS | | |

Performance Testing – Clinical

No clinical studies were required as appropriate verification and validation of the catheter and packaging modifications were achieved based on the similarities of the proposed device to the predicate device, and from results of bench testing.

Biocompatibility Testing

The CEREBASE DA Guide Sheath was assessed for biocompatibility in accordance with International Standard ISO 10993-1 "Biological Evaluation of Medical Devices – Part 1: Evaluation of Testing within a Risk Management Process." and FDA Guidance for Industry and FDA Staff: Use of International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing' (Issued June 16, 2016). The subject device is considered an externally communicating medical device with circulating blood contact for less than 24 hours. The following Biocompatibility Testing was completed as part of this evaluation:

VII. Non-Clinical Data Performance, Continued

| Table 6. Biocompatibility Test Results | | | |
|--|---|---|---|
| | Test | Test Summary | Conclusion |
| CEF | REBASE DA Guide Sheath | | |
| Cytotoxicity – ISO Elution Method | | Test articles exhibited no discrete intracytoplasmic granules, no cell lysis, no reduction of cell growth, resulting in a reactivity grade = 0 per ISO 10993-5. | PASS: Non- cytotoxic |
| | itization – ISO Guinea Pig imization Sensitization | No abnormal dermal reactions and no sensitization was observed. | PASS: Non- sensitizing |
| | Intracutaneous Reactivity | Injection sites appeared normal and no difference in erythema and edema scores from control. | PASS: Non- irritating |
| ISO Acute Systemic Toxicity in Mice | | Animals appeared clinically normal throughout the study upon observation. No deaths and no significant changes in body weight. | PASS: Non-toxic |
| USP Rabbit Material-Mediated Pyrogenicity | | Out of 3 animals, no single animal showed a total temperature rise of ≥ 0.5 °C, within USP requirements. | PASS: Non- pyrogenic |
| ility | ASTM Hemolysis | Hemolysis % was not higher than control in samples either in direct contact with the catheter or in samples extracted after contact with the catheter. | PASS: Non- hemolytic |
| Hemocompatibility | SC5b-9 Complement Activation Assay | SC5b-9 concentration of test article samples were not statistically higher than both negative control and activated normal human serum (NHS) controls. | PASS: Not a potential activator of the complement system |
| Неп | In Vivo Thromboresistance Study | Thrombus formation on the catheter was comparable to that on control article in similar animal vasculature. | PASS: Acceptable Thromboresistance |
| Hen | ostatic Valve | | |
| Cytotoxicity – ISO Elution Method | | Test articles exhibited no discrete intracytoplasmic granules, no cell lysis, no reduction of cell growth, resulting in a reactivity grade = 0 per ISO 10993-5. | PASS: Non- cytotoxic |
| | itization – ISO Guinea Pig imization Sensitization | No abnormal dermal reactions and no sensitization was observed. | PASS: Non- sensitizing |
| Irritation or Intracutaneous Reactivity | | Injection sites appeared normal. Mean erythema and edema scores of test articles had differences of <1 from control. | PASS: Non- irritating |
| ISO Acute Systemic Toxicity in Mice | | Animals appeared clinically normal throughout the study upon observation. No deaths and no significant changes in body weight. | PASS: Non-toxic |
| USP Rabbit Material-Mediated Pyrogenicity | | Out of 3 animals, no single animal showed a total temperature rise of ≥ 0.5 °C, within USP requirements. | PASS: Non- pyrogenic |
| Hemocompatibility: ASTM Hemolysis | | Hemolysis % was not higher than control in samples either in direct contact with the catheter or in samples extracted after contact with the valve. | PASS: Non- hemolytic |

(Table continued on next page)

VII. Non-Clinical Data Performance, Continued

| Table 6. Biocompatibility Test Results, Continued | | | |
|---|---|---|---|
| Test | | Test Summary | Conclusion |
| Dila | tor | | |
| Cytotoxicity – ISO Elution Method | | Test articles exhibited no discrete intracytoplasmic granules, no cell lysis, no reduction of cell growth, resulting in a reactivity grade = 0 per ISO 10993-5. | PASS: Non- cytotoxic |
| | itization – ISO Guinea Pig imization Sensitization | No abnormal dermal reactions and no sensitization was observed. | PASS: Non- sensitizing |
| ISO Intracutaneous Reactivity Study | | Injection sites appeared normal. Mean erythema and edema scores of test articles had differences of <1 from control. | PASS: Non- irritating |
| ISO Acute Systemic Toxicity in Mice | | Animals appeared clinically normal throughout the study upon observation. No deaths and no significant changes in body weight. | PASS: Non-toxic |
| USP Rabbit Material-Mediated Pyrogenicity | | Out of 3 animals, no single animal showed a total temperature rise of ≥ 0.5 °C, within USP requirements. | PASS: Non- pyrogenic |
| SC5b-9 Complete Activation Ass | ASTM Hemolysis | Hemolysis % was not higher than control in samples either in direct contact with the dilator or in samples extracted after contact with the dilator. | PASS: Non- hemolytic |
| | SC5b-9 Complement Activation Assay | SC5b-9 concentration of test article samples were not statistically higher than both negative control and activated normal human serum (NHS) controls. | PASS: Not a potential activator of the complement system |
| | In Vivo Thromboresistance Study | Thrombus formation on the dilator was comparable to that on control article in similar animal vasculature. | PASS: Acceptable Thromboresistance |
| Packaging | | | |
| Cytotoxicity – ISO Elution Method | | Test articles exhibited no discrete intracytoplasmic granules, no cell lysis, no reduction of cell growth, resulting in a reactivity grade = 0 per ISO 10993-5. | PASS: Non- cytotoxic |

VII. Non-Clinical Data Performance, Continued

Sterilization

The CEREBASE DA Guide Sheath, as packaged with included accessories, is sterilized using a validated 100% Ethylene Oxide sterilization process to ensure sterility assurance level (SAL) of 10⁻⁶ in accordance with ISO 11135-1: 2014, Sterilization of health-care products. Ethylene oxide. Requirements for the development, validation and routine control of a sterilization process for medical devices. The CEREBASE DA Guide Sheath and all accessories meet EO residuals per EN ISO 10993-7: 2009 Biological evaluation of medical devices. Ethylene oxide sterilization residuals for a limited contact delivery system – externally communicating. The CEREBASE DA Guide Sheath and all accessories are for single use only.

VIII. Conclusion

Based upon the intended use, design, materials, function, side-by-side in-vitro testing and animal testing, and passing biocompatibility test results, it is concluded that the subject device, CEREBASE DA Guide Sheath is substantially equivalent to the predicate device, Neuron MAX System (K111380, cleared 19 July 2011). The fundamental scientific technology is the same as the predicate device. The differences in verbiage in the Indications for Use statement only limits the locations that the subject device can be used and do not raise any questions regarding the safety and effectiveness of the device. Risk assessment of the CEREBASE DA and verification/validation testing confirmed the device is as safe and effective as the predicate device.